Pfizer Inc.
Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body
Last updated:
Abstract:
Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.
Status:
Grant
Type:
Utility
Filling date:
12 May 2016
Issue date:
16 Mar 2021